G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

NEXT STORY
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
PREV STORY
SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

author_avatar
NASDAQ Market News

ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy

author_avatar
NASDAQ Market News

Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021

author_avatar
NASDAQ Market News